.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,144,580

« Back to Dashboard

Details for Patent: 9,144,580

Title:Sodium thiosulfate-containing pharmaceutical compositions
Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
Inventor(s): Sherman; Craig (Scottsdale, AZ), Smith; Catherine Marie (Grafton, WI), Wirtz; Kevin Robert (Belgium, WI), Schulze; Erich (Mission Viejo, CA)
Assignee: Hope Medical Enterprises, Inc. (Scottsdale, AZ)
Filing Date:Mar 24, 2014
Application Number:14/222,766
Claims:1. A method for treating vascular calcification or calciphylaxis, comprising administering to a subject having vascular calcification or calciphylaxis, a therapeutically effective amount of pharmaceutical grade sodium thiosulfate pentahydrate, wherein the pharmaceutical grade sodium thiosulfate pentahydrate contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a water content between 32% and 37% by weight, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% of sulfite, contains no greater than about 0.5% of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the pharmaceutical grade sodium thiosulfate pentahydrate at 25.degree. C. is colorless and has a pH between about 6.0 and about 8.0, and wherein the pharmaceutical grade sodium thiosulfate pentahydrate is odorless crystals.

2. The method of claim 1, wherein vascular calcification is treated.

3. The method of claim 2, further comprising the administration of a diuretic, a renin inhibitor, a neutral endopeptidase inhibitor (NEP), a vasopeptidase inhibitor (dual NEP-ACE inhibitor), a HMG CoA reductase inhibitor, a bile sequestrant, anti-atherosclerotic agent, a calcium channel inhibitor, a potassium channel activator, an alpha-adrenergic agent, a beta-adrenergic agent, an antiarrhythmic agent, an ACAT inhibitor, a MTP inhibitor, a vasodilator, a platelet activating factor (PAF) antagonist, an anti-platelet agent, a P2Y(AC) antagonist, aspirin, or an anticoagulant.

4. The method of claim 3, wherein the diuretic is chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzothiazide, ethacrynic acid, ticrynafed, chlorothalidone, furosemide, muzolimine, bumetanide, triamterene, amiloride or spironoloactone.

5. The method of claim 3, wherein the vasopeptidase inhibitor is omapatrilat or gemopatrilat.

6. The method of claim 3, wherein the HMG CoA reductase inhibitor is pravastatin, lovastatin, atorvastatin, simvastatin, NK-104 (a.k.a. itavastatin, nisvastatin, or nisbastatin), and ZD-4522 (also know as rosuvastatin, atavastatin, or visatatin).

7. The method of claim 3, wherein the bile sequestrant is questran or niacin.

8. The method of claim 3, wherein the calcium channel blocker is amlodipine besylate.

9. The method of claim 3, wherein the beta-adrenergic agent is carvedilol or metoprolol.

10. The method of claim 3, wherein the vasodilator is a phosphodiesterase inhibitor, or sodium nitrite.

11. The method of claim 3, wherein the phosphodiesterase inhibitor is cilostazol, sildenafil, tadalafil, or vardenafil.

12. The method of claim 3, wherein the anti-platelet agent is abciximab, eptifibatide, or tirofiban.

13. The method of claim 3, wherein the P2Y(AC) antagonist is clopidogrel, itclopidine or CS-747.

14. The method of claim 3, wherein the anticoagulant is wafarin, a low molecular weight heparin, a Factor VIIa inhibitor, or a Factor Xa inhibitor.

15. The method of claim 14, wherein the low molecular weight heparin is enoxaparin.

16. The method of claim 1, wherein calciphylaxis is treated.

17. The method of claim 16, further comprising the administration of a hormonal agent, a diuretic or an anti-diabetic agent.

18. The method of claim 17, wherein the diuretic is chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzothiazide, ethacrynic acid, ticrynafed, chlorothalidone, furosemide, muzolimine, bumetanide, triamterene, amiloride or spironoloactone.

19. The method of claim 17, wherein the anti-diabetic agent is a biguanide, a glucosidase inhibitor, insulin, a meglitinide, a sulfonylurea, a thiozolidinediones, a PPAR-gamma agnonist, metformin, acarbose, repaglinide, flimepiride, glyburide, glipizide, troglitazone, rosiglitazone or pioglitazone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc